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Gonorrhoea: tackling the global epidemic in the era of rising antimicrobial resistance
Neisseria gonorrhoeae (NG), a sexually transmitted infection, remains a major global public 
health concern, estimated to have caused 87 million infections among 14-49 year olds in 
2016 worldwide(1), with rising rates particularly among men who have sex with men 
(MSM).(2)  Since the advent of effective antibiotic use in the 1930s, this pathogen has 
acquired resistance to most antibiotic classes used against it, and with the threat of 
increasingly resistant NG and dwindling treatment options, we are facing the very real 
possibility of untreatable NG.(3, 4) If not appropriately managed, gonorrhoea can result in 
severe sequelae such as pelvic inflammatory disease, infertility adverse pregnancy 
outcomes and newborn infections causing significant morbidity.(5) Gonorrhoea can also 
facilitate further transmission and increased risk of HIV.(6) To address this rising threat of 
gonorrhoea, we commissioned this Special Issue to summarize the latest updates on the 
burden of NG and inform strategies to control gonorrhoea in this era of rising antimicrobial 
resistance (AMR). It contains important reviews from global leaders in gonorrhoea and 
original research to better understand NG epidemics and patterns of resistance, gonorrhoea 
prevention, diagnosis and treatment including appropriate drug use for antibiotic 
stewardship (including the role of molecular diagnostics), and to provide an update on novel 
innovations. The Special Issue highlights the urgent need to invest in accelerating new 
antimicrobials against NG, point-of-care tests and promising vaccines. We thank the World 
Health Organization (WHO) for their generous sponsorship to make this Special Issue open-
access.
Understanding the burden of NG and NG-AMR
Kirkcaldy and colleagues, provides a global epidemiologic overview of the growing 
international threat of gonorrhoea, emphasizing the disproportionate burden among men 
who have sex with men (MSM), transgender individuals, racial/ethnic minorities and 
indigenous populations, sex workers and international travellers. There is a need to improve 
STI surveillance including collecting more data among key populations especially from 
transgender and adolescents as well as the burden of extragenital gonorrhoea. Unemo and 
colleagues, describes the critical work of the WHO Gonococcal Antimicrobial Surveillance 
Programme, a network of reference laboratories, established in 1990. The ‘real-world’ value 
of such a program is demonstrated by the data from 2015/16 of the susceptibility to 
ceftriaxone/cefixime, azithromycin and ciprofloxacin, and confirmed treatment failures with 
ceftriaxone with/without azithromycin or doxycycline. Further strengthening this program 
will be essential to provide the most up-to-date quality-assured surveillance data to ensure 
ongoing global surveillance of NG-AMR.
Callander and colleagues underscores the importance of reporting anatomical site-specific 
gonorrhoea diagnoses. The authors showed that the rise in gonorrhoea incidence among 
MSM attending Australian sexual health services, were disproportionate from rectal and 
oropharyngeal gonorrhoea.(7) This was not accounted for by use of diagnostic technology 
(nucleic acid amplification test (NAAT) vs. culture) and frequency of testing. Kohli and 
colleagues explore the role of Chemsex (using substances during sex to intensify and extend 
sexual sessions) in gonorrhoea diagnoses in the United Kingdom. They report that the use of 
crystal metamphetamine and gamma-hydroxybutyric acid (GHB) among MSM in the past 
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year was associated with twice the risk of gonorrhoea, and nearly four times the risk if men 
used all three chemsex drugs (+ mephedrone), compared to men reporting no use. To 
better understand the rise of NG in heterosexuals, Philipps and colleagues’ study examines a 
decade of data (2007-2017) from Melbourne, Australia to explore the risk factors associated 
with NG detection among heterosexual males. They report an 80% increase in urethral 
gonorrhoea diagnosis among high-risk and symptomatic heterosexual males between 2007 
and 2017 and highlight the need to better characterize the rise of NG in heterosexual 
networks and inform public health campaigns. 
Understanding NG case management
Loo and colleagues uncover suboptimal management of gonorrhoea in a hospital network in 
Australia, reminding us of the need for a concerted, broad public health response involving 
multiple stakeholders including hospital systems, if we are to control this epidemic. They 
examined five parameters of care - eliciting a sexual and travel history, culture of specimens 
for antimicrobial susceptibility testing, consideration of HIV testing, contact tracing to 
identify and treat other potential cases, and notification to health authorities for ongoing 
surveillance. These parameters provide a useful benchmark to evaluate the quality of NG 
case management in other settings.
Novel thinking is needed
To effectively control NG, new thinking is needed in several areas: prevention, diagnostics 
and management, particularly in the era of NG-AMR.
Novel primary prevention methods 
Non-antibiotic interventions and vaccinations are needed to stem the global rise of NG.(8) 
Gottlieb and colleagues review the data for gonorrhoea vaccination and efforts to advance 
viable gonococcal vaccine development, in light of a proof-of principle study demonstrating 
the cross-protection from the group B meningococcal outer membrane vesicle (OMV) 
vaccine to confer protection against NG.(9) The authors review promising vaccine 
candidates and describe the important activities of the Global STI Vaccine Roadmap. 
A growing body of work has arisen that demonstrates the importance of oropharyngeal 
transmission of gonorrhoea in the epidemic.(10) The oropharynx is an important 
environment where AMR strains may evolve. Therefore, using a mouthwash has been 
proposed as a novel method for gonorrhoea prevention(11) and we await the results from a 
randomised controlled trial (Oral Mouthwash use to Eradicate GonorrhoeaA, OMEGA trial) 
that examines whether daily mouthwash use could prevent incident gonorrhoea.(12) 
Philipps and colleagues explored the current practice of mouthwash use among MSM and 
its association with oral sex practices, and show that currently there is no association 
between frequent mouthwash use and oral sex practices,(13) suggesting a need for public 
education if mouthwash is shown to be effective in preventing gonorrhoea. Chow and 
colleagues’ timely review addresses the practical question of what are the evidence gaps in 
implementing mouthwash use as a public health campaign.(14) The authors also raise 
practical questions that remain e.g. which mouthwash works (out of all the products 
available), optimal frequency, time, volume, how to use it (gargle), and timing (post-sex, 
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daily).
Novel diagnostics using molecular tests
AMR to the first-line NG treatment of ceftriaxone plus azithromycin has now been reported. 
A diagnostic-based antibiotic stewardship strategy is urgently needed to 1) identify the 
etiologic agent through a rapid easy to use point-of-care test (e.g. differentiate CT/NG) to 
ensure immediate treatment with the right antibiotic that may reduce over-treatment, 
follow-up and onward transmission; and 2) identify susceptible strains through a near 
patient AMR diagnostic (e.g. for ciprofloxacin susceptibility) to conserve current regimen 
and future treatment. Currently there are several well-characterised molecular AMR 
determinants that can be used for effective prediction of AMR in NG, particularly for 
ciprofloxacin, but less adequately for azithromycin, cefixime and ceftriaxone.  Hall and 
colleagues’ timely and important review describes the resistance-associated genotype 
markers with phenotypic resistance to fluoroquinolones and macrolides. They found that 
the S91 and D95 mutations in the GyrA protein had high sensitivity (98.6%, 95% CI: 98.0-
99%) and specificity (91.4%, 95% CI: 88.6-93.7) for ciprofloxacin resistance. Cefixime, a third-
generation extended-spectrum cephalosporin, is one of few antibiotics that NG is 
susceptible to. Deng and colleagues’ systematic review describes the molecular 
characteristics and potential mechanisms for gonococcal resistance to cefixime, gives critical 
information for optimal targets for molecular assays seeking to predict cefixime 
susceptibility. Together, these data are helpful in assessing potential accuracy of these 
markers for AMR diagnostic platforms.
Diagnostics are critical in characterizing NG strains that fail treatment. Buckley and 
colleagues highlight the importance of strengthening methods to verify gonorrhoea 
treatment failures. They reinvestigated the two Australian cases associated with treatment 
failure with ceftriaxone, using whole genome sequencing (WGS) to provide better 
discrimination between strains rather than traditional Sanger sequencing (which examines 
two highly variable regions). Whilst WGS offers faster and better prediction, and the ability 
to compare with similar cases elsewhere, the cost-effectiveness of WGS would need to be 
further explored, particularly in light of decreasing prices over time of this technology.
Novel management
Most countries use ceftriaxone or cefixime plus azithromycin in their empiric treatment of 
NG. There are now debates on the use of azithromycin as dual therapy for gonorrhoea, as 
well as treatment of chlamydial infection due to increasing resistance to NG, as well as 
Mycoplasma genitalium. Mensforth and colleagues’ review tackles the practical issue of 
how to wisely use azithromycin for gonorrhoea management: reviewing evidence for its use 
as monotherapy, dual therapy and its impact on other STIs. They challenge the use of 1 g 
Azithromycin as part of dual therapy. With very little second-line options available, Lewis 
reviews the search for new agents to manage NG and find that the pipeline is 
disappointingly sparse. The authors discuss the latest evidence for ertapenem, modern 
fluoroquinolones (gemifloxacin, sitafloxacin, delafloxacin), solithromycin, gepotidacin, and 
zoliflodacin, though none obviously emerge as a clear winning candidate.
To tackle an “old foe”, there is a pressing need for new thinking in how we approach the 
foundations for controlling an STI: better primary prevention methods (through vaccination, 
Page 3 of 5
www.publish.csiro.au/journals/sh
Sexual Health
For Review Only
mouthwash and smarter condom promotion), earlier detection (of the index case and their 
partners) and appropriate antimicrobial treatment (through improved diagnostic 
capabilities, antimicrobial stewardship and search for new antimicrobials) and a stronger 
inter-connected global surveillance systems to better inform public health guidelines and 
policies. We hope that the articles within this Special Issue provides you with an overview of 
the latest thinking and novel approaches for the control of NG and spurs new ideas to tackle 
the global epidemic of gonorrhoea. 
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